Table II:

First post-BTKi therapy (N=149)

Treatment	n (%)
Chemotherapies (+/− antibodies)	78 (52.3)
R-BAC	11 (7.4)
BR	25 (15.8)
Cytarabine-containing regimens	16 (10.7)
Gemcitabine-containing regimens	4 (2.7)
Other chemotherapy (+/− antibodies)	22 (14.8)
Targeted therapies (+/−antibodies)	67 (45.0)
BTKi regimens	8 (5.4)
Lenalidomide-containing regimens	26 (17.4)
Bortezomib-containing regimens	13 (8.7)
Temsirolimus-containing regimens	1 (0.7)
Other targeted therapies (+/−antibodies)	19 (12.8)
Others	4 (2.7)
Radiotherapy	4 (2.7)

Abbreviations: BR, bendamustine + rituximab; BTKi, Bruton tyrosine kinase inhibitor; R-BAC, rituximab + bendamustine + cytarabine